BN-50726

• Description:

  BN-50726 is a potent platelet-activating factor (PAF) receptor antagonist. BN-50726 inhibits PAF-induced effects (e.g., [3H]-serotonin release and hypotension) (IC50=5.40 nM) . BN-50726 is promising for research of PAF-mediated pathological processes (e.g., inflammation, anaphylaxis, hypotension) [1][2].

• UNSPSC:

  12352005

• Target:

  Platelet-activating Factor Receptor (PAFR)

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Smiles:

  CC1=NN=C2N1C3=C(C4=C(CN(S(=O)(CCCCCCCCCCCCCCCC)=O)CC4)S3)C(C5=CC=CC=C5Cl)=NC2

• Molecular Formula:

  C34H48ClN5O2S2

• Molecular Weight:

  658.36

• References & Citations:

  [1]Zarco P, et al. Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol. 1992 May;88 (2) :318-23.|[2]Yue TL, et al. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo. Prostaglandins. 1990 May;39 (5) :469-80.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [127279-06-5]